Drug Combination Details
| General Information of the Combination (ID: C98820) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | Lapatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | FOXO3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GADD45A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | NQO1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | ||
| ZR-75-1 | CVCL_0588 | Invasive breast carcinoma | Homo sapiens | |||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | Xenograft nude mice were inoculated subcutaneously with 0.1 mL of cell suspension (ZR-75-1 and BT-474 cells). | |||||
| Experimental
Result(s) |
Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. | |||||
